↓ Skip to main content

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

Overview of attention for article published in Frontiers in immunology, April 2022
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors
Published in
Frontiers in immunology, April 2022
DOI 10.3389/fimmu.2022.845417
Pubmed ID
Authors

James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 16%
Student > Ph. D. Student 3 12%
Unspecified 2 8%
Student > Master 2 8%
Student > Bachelor 1 4%
Other 3 12%
Unknown 10 40%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 12%
Immunology and Microbiology 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Unspecified 2 8%
Medicine and Dentistry 2 8%
Other 3 12%
Unknown 10 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2022.
All research outputs
#21,451,622
of 26,411,386 outputs
Outputs from Frontiers in immunology
#26,053
of 33,432 outputs
Outputs of similar age
#342,758
of 455,520 outputs
Outputs of similar age from Frontiers in immunology
#1,331
of 1,669 outputs
Altmetric has tracked 26,411,386 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,432 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 455,520 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,669 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.